Product
Supplier
Encyclopedia
Inquiry
Home > Encyclopedia > 3,5-Pyridinedicarboxylic acid, 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-, 3-methyl 5-[(1-oxobutoxy)methyl] ester

3,5-Pyridinedicarboxylic acid, 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-, 3-methyl 5-[(1-oxobutoxy)methyl] ester

pharmaceutical raw materials
3,5-Pyridinedicarboxylic acid, 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-, 3-methyl 5-[(1-oxobutoxy)methyl] ester structure

3,5-Pyridinedicarboxylic acid, 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-, 3-methyl 5-[(1-oxobutoxy)methyl] ester 

structure
  • CAS No:

    167221-71-8

  • Formula:

    C21H23Cl2NO6

  • Chemical Name:

    3,5-Pyridinedicarboxylic acid, 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-, 3-methyl 5-[(1-oxobutoxy)methyl] ester

  • Synonyms:

    3,5-Pyridinedicarboxylic acid,4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-,3-methyl 5-[(1-oxobutoxy)methyl] ester;3,5-Pyridinedicarboxylic acid,4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-,methyl (1-oxobutoxy)methyl ester;Clevidipine;rac-Clevidipine;Clevelox;H 324/38;Cleviprex;166432-28-6

  • Categories:

    Active Pharmaceutical Ingredients  >  Circulatory System Drugs

Description

White to Off-White SolidClevidipine is an ultra-short-acting vasodilator of the dihydropyridine (DHP) class of CCB. It is indicated as an intravenous treatment for the acute management of hypertension when oral therapy is not feasible or not desirable. Clevidipine is the second intravenous CCB to be marketed behind nicardipine for this indication. Both agents are primarily used for urgent treatment of hypertension in cardiac surgical setting, intensive care units, and emergency department


Clevidipine is a dihydropyridine.|Clevidipine is a dihydropyridine L-type calcium channel blocker that is selective for vascular smooth muscle and is indicated for blood pressure reduction when oral therapy is not an option.

3,5-Pyridinedicarboxylic acid, 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-, 3-methyl 5-[(1-oxobutoxy)methyl] ester Basic Attributes

456.32

456.32

1312995-182-4

DTXSID6057661

C08CA16|C - Cardiovascular system

29339900

Characteristics

90.9

4.3

Powder

1.289

128-130°C

539.7±50.0 °C(Predicted)

280℃

1.543

Refrigerator

Safety Information

24/25

P201, P202, P281, P308+P313, P405, P501

H361

|Warning|H361 (100%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]|P201, P202, P281, P308+P313, P405, and P501|The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory.

Toxicity

>99.5%

Drug Information

For the reduction of blood pressure when when oral antihypertensive therapy is not feasible or not desirable.|FDA Label|Treatment of hypertensive disease

Clevidipine belongs to a well-known class of drugs called dihydropyridine calcium channel antagonists. Clevidpine is the first third generation intravenous dihydropyridine calcium channel blocker. In vitro studies demonstrated that clevidipine acts by selectively relaxing the smooth muscle cells that line small arteries, resulting in arterial dilation, widening of the artery opening, and without reducing central venous pressure or reducing cardiac output.

A class of drugs that act by selective inhibition of calcium influx through cellular membranes. (See all compounds classified as Calcium Channel Blockers.)

urine 63-74%, feces 7-22%

Clevidipine is rapidly hydrolyzed to inactive metabolites by esterases in arterial blood.

1 minute

Possibly by deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum, clevidipine inhibits the influx of extracellular calcium across both the myocardial and vascular smooth muscle cell membranes. The resultant inhibition of the contractile processes of the myocardial smooth muscle cells leads to dilation of the coronary and systemic arteries and improved oxygen delivery to the myocardial tissue.

butyroxymethyl methyl 4-(2',3'-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate

3,5-Pyridinedicarboxylic acid, 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-, 3-methyl 5-[(1-oxobutoxy)methyl] ester Use and Manufacturing

Uses

A calcium channel protein inhibitor and blocker

Human Drugs -> EU pediatric investigation plans|Human Drugs -> FDA Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) -> Active Ingredients

Computed Properties

Molecular Weight:456.3
XLogP3:4.3
Hydrogen Bond Donor Count:1
Hydrogen Bond Acceptor Count:7
Rotatable Bond Count:10
Exact Mass:455.0902428
Monoisotopic Mass:455.0902428
Topological Polar Surface Area:90.9
Heavy Atom Count:30
Complexity:748
Undefined Atom Stereocenter Count:1
Covalently-Bonded Unit Count:1
Compound Is Canonicalized:Yes

Recommended Suppliers of 3,5-Pyridinedicarboxylic acid, 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-, 3-methyl 5-[(1-oxobutoxy)methyl] ester

Latest News on 3,5-Pyridinedicarboxylic acid, 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-, 3-methyl 5-[(1-oxobutoxy)methyl] ester

Scan the QR Code to Share

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.